2025-08-12-港交所-华夏沪深三百_华夏沪深三百－Ｒ_2025中期报告页_36页_743kb

ChinaAMC CSI 300 Index ETF Summary

Core Information

• Sub-Fund Name: ChinaAMC CSI 300 Index ETF
• Parent Fund Series: ChinaAMC ETF Series
• Established Under: Hong Kong law, trust deed dated 28 May 2012
• Trading Dates:
  • RMB Counter: 17 July 2012
  • HKD Counter: 26 October 2012
• Index Tracked: CSI 300 Index
• Investment Strategy:
  • Full replication strategy (investing in the same weightings as the Index)
  • Representative sampling strategy (if direct investment is not possible)
• RQFII Status: Granted by the China Securities Regulatory Commission
• Stock Connect: Used to achieve mutual stock market access between mainland China and Hong Kong

Key Financial Highlights (1 January 2025 to 30 June 2025)

• Total Assets: 16,965,270,708 RMB
• Total Liabilities: 15,490,353 RMB
• Net Assets Attributable to Unitholders: 16,949,780,355 RMB
• Total Cash and Cash Equivalents: 167,362,302 RMB
• Number of Units Outstanding: 413,400,000
• Net Asset Value (NAV) per Unit: 41.0009 RMB

Performance Record

• The Index total return since launch was 117.68%.
• The Sub-Fund total return since launch was 90.12% for RMB NAV-to-NAV and 89.07% for RMB Market-to-Market.

Activities of the Sub-Fund

• Average Daily Trading Volume: ~2,049,638 units
• Units Issued During Period: 277,500,000
• Units Redeemed During Period: 357,900,000

Investment Portfolio Overview (As of 30 June 2025)

• Total Financial Assets at Fair Value Through Profit or Loss: 16,678,763,250 RMB
• Key Holdings:
  • Consumer Discretionary: BYD Co Ltd (1.29%), Midea Group Co Ltd (1.52%), Seres Group Co Ltd (0.47%)
  • Consumer Staples: Kweichow Moutai Co Ltd (3.79%), Wuliangye Yibin Co Ltd (0.99%), China Resources Sanjiu Medical & Pharmaceutical Co Ltd (0.09%)
  • Energy: China Shenhua Energy Co Ltd (0.57%), China Petroleum & Chemical Corp (0.35%), CNOOC Ltd (0.27%)
  • Financials: China Merchants Bank Co Ltd (2.44%), Ping An Insurance Group Co of China Ltd (2.56%), Industrial Bank Co Ltd (1.66%)
  • Health Care: Aier Eye Hospital Group Co Ltd (0.25%), Beijing Wantai Biological Pharmacy Enterprise Co Ltd (0.10%), Beijing Tong Ren Tang Co Ltd (0.11%)

Financial Statements

Statement of Financial Position

• Total Assets: 16,965,270,708 RMB (vs. 20,115,385,299 RMB as of 31 December 2024)
• Total Liabilities: 15,490,353 RMB (vs. 34,017,368 RMB as of 31 December 2024)
• Net Assets Attributable to Unitholders: 16,949,780,355 RMB (vs. 20,081,367,931 RMB as of 31 December 2024)

Statement of Comprehensive Income

• Total Comprehensive Income: 20,463,063 RMB
• Profit Before Tax: 41,202,866 RMB
• Withholding Income Tax Expenses: 20,739,803 RMB
• Net Investment (Losses)/Gains: -74,282,637 RMB

Statement of Changes in Net Assets

• Net Assets at Beginning: 20,081,367,931 RMB
• Issue of Units: 11,248,145,249 RMB
• Redemption of Units: -14,400,195,888 RMB
• Net Assets at End: 16,949,780,355 RMB

Statement of Cash Flows

• Net Increase in Cash and Cash Equivalents: 42,013,868 RMB
• Cash and Cash Equivalents at Beginning: 125,348,434 RMB
• Cash and Cash Equivalents at End: 167,362,302 RMB
• Net Cash Flows from Operating Activities: 3,193,988,457 RMB
• Net Cash Flows from Financing Activities: -3,151,974,589 RMB

Key Notes

• The report is unaudited and prepared in accordance with the same accounting policies as the 2024 annual financial statements.
• The performance of the Sub-Fund may not match the Index due to market conditions, transaction costs, and other factors.
• Investors should not rely solely on this report for investment decisions.
• Important Disclaimer: Any opinion expressed in this report reflects the Manager's view and is subject to change.
• For more details, refer to the prospectus available at https://www.chinaamc.com.hk/product/chinaamc-csi-300-index-utf-3188-hk-83188-hk/#prospectusDocuments